JP6234476B2 - メラノーマ細胞に対抗するためのデルフィニジン - Google Patents

メラノーマ細胞に対抗するためのデルフィニジン Download PDF

Info

Publication number
JP6234476B2
JP6234476B2 JP2015546930A JP2015546930A JP6234476B2 JP 6234476 B2 JP6234476 B2 JP 6234476B2 JP 2015546930 A JP2015546930 A JP 2015546930A JP 2015546930 A JP2015546930 A JP 2015546930A JP 6234476 B2 JP6234476 B2 JP 6234476B2
Authority
JP
Japan
Prior art keywords
delphinidin
composition according
cells
complex
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015546930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502985A (ja
JP2016502985A5 (cg-RX-API-DMAC7.html
Inventor
ノルベルト・レーヴァー
イェンス・ブロシャイト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapiotec GmbH
Original Assignee
Sapiotec GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapiotec GmbH filed Critical Sapiotec GmbH
Publication of JP2016502985A publication Critical patent/JP2016502985A/ja
Publication of JP2016502985A5 publication Critical patent/JP2016502985A5/ja
Application granted granted Critical
Publication of JP6234476B2 publication Critical patent/JP6234476B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
JP2015546930A 2012-12-11 2013-11-28 メラノーマ細胞に対抗するためのデルフィニジン Expired - Fee Related JP6234476B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102012222777.6 2012-12-11
DE102012222777 2012-12-11
EP13150909.3 2013-01-11
EP13150909 2013-01-11
PCT/EP2013/074991 WO2014090586A1 (de) 2012-12-11 2013-11-28 Delphinidin zur bekämpfung von melanomzellen

Publications (3)

Publication Number Publication Date
JP2016502985A JP2016502985A (ja) 2016-02-01
JP2016502985A5 JP2016502985A5 (cg-RX-API-DMAC7.html) 2016-11-10
JP6234476B2 true JP6234476B2 (ja) 2017-11-22

Family

ID=49679524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015546927A Expired - Fee Related JP6234475B2 (ja) 2012-12-11 2013-11-28 メラノーマ細胞に対抗するためのデルフィニジン
JP2015546930A Expired - Fee Related JP6234476B2 (ja) 2012-12-11 2013-11-28 メラノーマ細胞に対抗するためのデルフィニジン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015546927A Expired - Fee Related JP6234475B2 (ja) 2012-12-11 2013-11-28 メラノーマ細胞に対抗するためのデルフィニジン

Country Status (8)

Country Link
US (2) US9949947B2 (cg-RX-API-DMAC7.html)
EP (2) EP2931287B1 (cg-RX-API-DMAC7.html)
JP (2) JP6234475B2 (cg-RX-API-DMAC7.html)
KR (2) KR102164174B1 (cg-RX-API-DMAC7.html)
CN (2) CN104936601A (cg-RX-API-DMAC7.html)
CA (2) CA2893883A1 (cg-RX-API-DMAC7.html)
HK (1) HK1215392A1 (cg-RX-API-DMAC7.html)
WO (2) WO2014090583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CN104936601A (zh) * 2012-12-11 2015-09-23 赛博尔泰克股份公司 用于对抗黑色素瘤细胞的飞燕草素

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946228A (ja) 1982-09-08 1984-03-15 Zeria Shinyaku Kogyo Kk 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
HU199444B (en) 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
GB8907008D0 (en) 1989-03-28 1989-05-10 Inverni Della Beffa Spa Intermediates useful for the synthesis for delphinidin chloride
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
DE69635480T2 (de) * 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
GB2307176A (en) 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
JP4101346B2 (ja) 1998-02-18 2008-06-18 ダイセル化学工業株式会社 酸化触媒系及びそれを用いた酸化方法
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
JP2003506458A (ja) 1999-08-11 2003-02-18 ジョセフ ピサ， シクロデキストリン誘導体の包接複合体形成の増強
AU7937500A (en) 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
ES2250460T3 (es) 2000-09-12 2006-04-16 Meiji Seika Kaisha, Ltd. Procedimiento para la preparacion de glucosido de antocianidina purificado.
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
JP2003171274A (ja) 2001-12-07 2003-06-17 Tomihiko Higuchi 薬剤耐性菌感染症治療のための医薬組成物および消毒剤
CN1625414A (zh) 2002-02-01 2005-06-08 施摩达生物技术有限公司 药物组合物
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
CN101912615B (zh) 2003-03-28 2013-03-27 阿莱斯贸易有限公司 用于改善的经口和透粘膜输送的克拉屈滨制剂
WO2005067905A1 (ja) 2004-01-14 2005-07-28 Otsuka Pharmaceutical Factory, Inc. プロポフォール含有脂肪乳剤
CN1317961C (zh) 2004-03-25 2007-05-30 吴朝琴 冻干草莓加工工艺
CN100342026C (zh) * 2004-05-13 2007-10-10 深圳新鹏生物工程有限公司 重组人可溶性肿瘤坏死因子相关凋亡诱导配体制备方法
WO2006076387A2 (en) * 2005-01-11 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Cyanidin-3-glucoside as an anti-neoplastic agent
DE102005017775A1 (de) 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
KR100733913B1 (ko) * 2005-08-30 2007-07-02 한국화학연구원 안토시아닌을 포함하는 뇌세포 보호제와 뇌경색 및 뇌졸중예방 또는 치료제
US7645748B2 (en) * 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
EP2099408B1 (en) 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
KR100756656B1 (ko) 2006-12-12 2007-09-10 한국화학연구원 안토시아닌을 포함하는 뇌경색 또는 뇌졸중 예방 및 개선용건강식품
KR100880876B1 (ko) 2007-04-11 2009-01-30 경상대학교산학협력단 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 피판이나조직의 허혈-재관류 손상의 예방 또는 치료용 의약 조성물
US20090082400A1 (en) 2007-07-31 2009-03-26 Ving Lee Soluble pyrone analogs methods and compositions
JP5574600B2 (ja) 2007-12-17 2014-08-20 日本製薬工業株式会社 吸収性骨疾患の予防・治療剤
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010110328A1 (ja) 2009-03-25 2010-09-30 三栄源エフ・エフ・アイ株式会社 水易溶性イソクエルシトリン組成物
WO2010141760A2 (en) 2009-06-05 2010-12-09 The Regents Of The University Of Colorado, A Body Corporate Antimicrobial peptides
ES2618952T3 (es) 2009-10-21 2017-06-22 Maqui New Life S.A. Composiciones que incluyen antocianidinas y métodos de uso
EP2345427A1 (de) 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
CA2792733C (en) 2010-03-13 2015-06-02 Eastpond Laboratories Limited Fat-binding compositions comprising .alpha.- or .beta.-cyclodextrin
DE102010042615A1 (de) 2010-10-19 2012-04-19 Wacker Chemie Ag 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel
BR112013016809A2 (pt) 2010-12-31 2016-09-27 Eastpond Lab Ltd composições de hidratação celular
DK2484350T3 (en) 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
WO2013144303A1 (de) 2012-03-30 2013-10-03 Sapiotec Gmbh Antibakterielle wirkstoffe auf der basis anthocyanidin- cyclodextrin- komplexen
EP2831122B1 (de) 2012-03-30 2016-02-03 SapioTec GmbH Anthocyanidin-komplex
WO2014060548A1 (de) 2012-10-17 2014-04-24 Sapiotec Gmbh Anthocyanidin-komplex zur behandlung von multiplem myelom
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
CN104936601A (zh) * 2012-12-11 2015-09-23 赛博尔泰克股份公司 用于对抗黑色素瘤细胞的飞燕草素
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
EP2913366A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex

Also Published As

Publication number Publication date
KR20150107742A (ko) 2015-09-23
JP2016502984A (ja) 2016-02-01
CA2893881C (en) 2020-09-22
US20150328336A1 (en) 2015-11-19
EP2931287A1 (de) 2015-10-21
US20150320719A1 (en) 2015-11-12
US9511047B2 (en) 2016-12-06
CA2893883A1 (en) 2014-06-19
KR20150107741A (ko) 2015-09-23
US9949947B2 (en) 2018-04-24
KR102164174B1 (ko) 2020-10-12
CN104936601A (zh) 2015-09-23
EP2931286B1 (de) 2017-10-04
JP6234475B2 (ja) 2017-11-22
CA2893881A1 (en) 2014-06-19
EP2931287B1 (de) 2017-10-04
WO2014090583A1 (de) 2014-06-19
HK1216229A1 (zh) 2016-10-28
JP2016502985A (ja) 2016-02-01
EP2931286A1 (de) 2015-10-21
HK1215392A1 (zh) 2016-08-26
WO2014090586A1 (de) 2014-06-19
CN104918622A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
Huang et al. The genotype-dependent influence of functionalized multiwalled carbon nanotubes on fetal development
Onodera et al. Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin
Kemp et al. Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesisproperties
Joseph et al. Galactoxyloglucan-modified nanocarriers of doxorubicin for improved tumor-targeted drug delivery with minimal toxicity
Xiao et al. Engineering cannabidiol synergistic carbon monoxide nanocomplexes to enhance cancer therapy via excessive autophagy
Yi et al. Enhanced response of tamoxifen toward the cancer cells using a combination of chemotherapy and photothermal ablation induced by lentinan-functionalized multi-walled carbon nanotubes
Hu et al. The rational design of NAMI-A-loaded mesoporous silica nanoparticles as antiangiogenic nanosystems
JP5663741B2 (ja) アミノ酸抱合シアノアクリレートポリマー粒子
Liu et al. Metal-organic frameworks as protective matrices for peptide therapeutics
Chan et al. Cancer-targeted tri-block copolymer nanoparticles as payloads of metal complexes to achieve enhanced cancer theranosis
Zhou et al. Development and investigation of dual potent anticancer drug-loaded nanoparticles for the treatment of lung cancer therapy
JP6234476B2 (ja) メラノーマ細胞に対抗するためのデルフィニジン
Chen et al. Bufotalin loaded biomimetic nanodrug for combined chemo/photodynamic therapy of cancer
Huang et al. Copper-coordinated nanomedicine for the concurrent treatment of lung cancer through the induction of cuproptosis and apoptosis
Wu et al. Fluorescent hyaluronic acid nanoprodrug: A tumor-activated autophagy inhibitor for synergistic cancer therapy
US12128111B2 (en) Glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and preparation method thereof
CN104780925A (zh) 用于治疗多发性骨髓瘤的花青素络合物
Xu et al. Coomassie Bright Blue-Conjugated Human Serum Albumin Nanoparticles as a Tumor-Selective Weapon for Leukemia Therapy
Chen et al. Ultrasmall Ag6Cu2 clusters for accelerating wound healing through the activation of antibacterial activity and endogenous anti-inflammatory property
HK1216229B (en) Delphinidin for combating melanoma cells
Rossi et al. Role of the pharmaceutical excipients in the tamoxifen activity on MCF-7 and vero cell cultures
Li et al. A mitochondria-targeted nanozyme for myocardial ischemia/reperfusion injury with synergistic antioxidant and anti-inflammatory properties
Hasan et al. Liver-Specific Nanoparticle-Mediated Delivery and MMP-Triggered Release of Veratridine, a Potent Pro-Apoptotic Molecule, to Effectively Target Metastatic Colorectal Cancer
Zhao et al. Synergistic Anticancer Response of Curcumin and Piperine Loaded Lignin-gp (NIPAM-co-DMAEMA) Gold Nanogels Against Glioblastoma Multiforme
CN120267849A (zh) 一种靶向双硫死亡的载6-氨基烟酰胺纳米材料及其制备方法和在卵巢癌中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171024

R150 Certificate of patent or registration of utility model

Ref document number: 6234476

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees